Articles from Viveve Medical, Inc.

ENGLEWOOD, CO / ACCESSWIRE / July 28, 2022 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its second quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, August 11, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.

ENGLEWOOD, CO / ACCESSWIRE / July 12, 2022 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that the Taiwan Intellectual Property Office (TIPO) recently issued Taiwan Patent No. I766557 for Viveve's dual-energy technology. The awarded patent further expands and strengthens Viveve's intellectual property portfolio in one of Asia's key markets.

ENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright Global Investment Conference, May 23 - 26, 2022. Mr. Durbin will deliver the Viveve corporate presentation and meet with investment community members during the hybrid conference. Event: H.C. Wainwright Global

Durbin recognized for second consecutive year for leading development of Viveve's innovative technology for treatment of stress urinary incontinence in women ENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's intimate health, announced today that Scott Durbin, the Company's Chief Executive Officer, has been named by Healthcare Technology Report as one of The Top 50

Total revenue of $1.6 million in Q1 including sale of 2,750 consumable treatment tips PURSUIT trial top-line results anticipated at end of 2022 Conference call to be hosted by Company at 5:00 PM ET today ENGLEWOOD, CO / ACCESSWIRE / May 12, 2022 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's intimate health, today reported financial results for the quarter ended March 31, 2022, and will provide a

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

Reported total revenue for year end 2021 of $6.4 million representing 17% year-over-year growth Enrollment completed in U.S. pivotal PURSUIT trial for stress urinary incontinence and 12-month post treatment follow-up visits underway PURSUIT top-line results anticipated at end of 2022 Conference call to be hosted by Company at 5:00 PM ET today ENGLEWOOD, CO / ACCESSWIRE / March 17, 2022 / Viveve Medical, Inc. (NASDAQVIVE), a medical

ENGLEWOOD, CO / ACCESSWIRE / March 3, 2022 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's intimate health, today announced that it will report its full year 2021 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, March 17, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day. The full year 2021 results conference call

Viveve SVP Suzon Lommel named to list for second consecutive year for efforts to advance innovative technologies to treat stress urinary incontinence in women ENGLEWOOD, CO / ACCESSWIRE / January 13, 2022 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's intimate health, announced today that Suzon Lommel, the Company's Senior Vice President of Regulatory and Quality Affairs, has been named by The Healthcare

ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright BIOCONNECT Conference, January 10 - 13, 2022. Mr. Durbin will deliver the Viveve corporate presentation and meet with investment community members during the virtual conference. Event: H.C. Wainwright

Major milestone achieved in Company's advance toward a new U.S. SUI indication ENGLEWOOD, CO / ACCESSWIRE / December 14, 2021 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's intimate health, announced today that it has completed enrollment in its pivotal PURSUIT clinical trial to assess the efficacy and safety of the Viveve procedure in the treatment of stress urinary incontinence (SUI) in women. Positive

- Total revenue of $1.6M reported for Q3 - Pivotal SUI PURSUIT trial enrollment nears completion - randomizations on-track for completion in Q4 ENGLEWOOD, CO / ACCESSWIRE / November 11, 2021 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's intimate health, today reported financial results for the quarter ended September 30, 2021, and will provide a corporate update on its scheduled conference call at 5:00 PM

ENGLEWOOD, CO / ACCESSWIRE / November 2, 2021 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's intimate health, today announced that it will report its third quarter 2021 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, November 11, 2021. The Company will hold a conference call and webcast at 5:00 PM ET the same day. The Company's 10-Q documents will

Issuance further expands and strengthens Company's intellectual property portfolio ENGLEWOOD, CO / ACCESSWIRE / October 28, 2021 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's intimate health, today announced that the United States Patent and Trademark Office (USPTO) recently issued U.S. Patent No. 11,154,349. The awarded patent further strengthens the Company's intellectual property portfolio and

Patent strengthens and expands Viveve's intellectual property portfolio for the treatment of stress urinary incontinence ENGLEWOOD, CO / ACCESSWIRE / September 23, 2021 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's intimate health, today announced that the Australian Patent Office has issued Patent No. 2016324168 covering Viveve's unique method of treatment to address stress urinary incontinence (SUI) in

ENGLEWOOD, CO / ACCESSWIRE / September 7, 2021 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, September 13 - 15, 2021. Mr. Durbin will deliver the Viveve corporate presentation and meet with investment community members during the virtual

Total revenue of $1.7M reported for Q2 Reported sales of approximately 3,500 consumable treatment tips - a 42% unit increase quarter-over-quarter Pivotal SUI PURSUIT trial enrollment on-track for completion in early Q4 Potential long-term reimbursement pathway established with new Category III CPT® code ENGLEWOOD, CO / ACCESSWIRE / August 12, 2021 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's

ENGLEWOOD, CO / ACCESSWIRE / August 5, 2021 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's intimate health, today announced that it will report its second quarter 2021 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, August 12, 2021. The Company will hold a conference call and webcast at 5:00 PM ET the same day. The conference call may be accessed

ENGLEWOOD, CO / ACCESSWIRE / August 3, 2021 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's intimate health, today announced that the Canadian Intellectual Property Office (CIPO) recently issued Canadian Patent No. 3028905 for Viveve's dual-energy technology device and method. The awarded patent further strengthens the Company's intellectual property portfolio. "We are pleased with the issuance of the

New code approved by American Medical Association and supported by key medical societies Long-term pathway for potential reimbursement now established for Company's dual-energy noninvasive treatment for urethral hypermobility to improve stress urinary incontinence in women ENGLEWOOD, CO / ACCESSWIRE / July 7, 2021 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's intimate health, today announced that the

ENGLEWOOD, CO / ACCESSWIRE / July 6, 2021 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will participate in the Ladenburg Thalmann Healthcare Conference, July 13 - 14, 2021. Mr. Durbin will deliver the Viveve corporate presentation and meet with investment community members during the virtual conference. Event: Ladenburg Thalmann

ENGLEWOOD, CO / ACCESSWIRE / June 10, 2021 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's intimate health, today announced that the United States Patent and Trademark Office (USPTO) recently issued U.S. Patent No. 10,980,596 for Viveve's dual-energy technology device. The awarded patent further strengthens the Company's intellectual property portfolio and expands its patent claims in the U.S. "We are

Meeting scheduled to reconvene June 23, 2021 at 12:00 PM Eastern Time Company encourages stockholders to cast their votes ENGLEWOOD, CO / ACCESSWIRE / June 2, 2021 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's intimate health, today announced that it has adjourned its 2021 Annual Meeting of Stockholders for a second time due to a lack of quorum. The adjourned meeting will be held at 12:00

Pivotal SUI PURSUIT trial enrollment underway and accelerating Total revenue of $1.5M for Q1 including sale of 2,450 consumable treatment tips Strengthened patent portfolio in key Asia Pacific markets ENGLEWOOD, CO / ACCESSWIRE / May 13, 2021 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's intimate health, today reported financial results for the quarter ended March 31, 2021, and will

- Meeting scheduled to reconvene June 2, 2021 at 12:00 PM Eastern Time - Company encourages stockholders to cast their votes ENGLEWOOD, CO / ACCESSWIRE / May 11, 2021 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's intimate health, today announced that it has adjourned its 2021 Annual Meeting of Stockholders due to a lack of quorum. The adjourned meeting will be held at 12:00 PM Eastern Time

ENGLEWOOD, CO / ACCESSWIRE / May 6, 2021 / Viveve Medical, Inc. (NASDAQVIVE), a medical technology company focused on women's intimate health, today announced that it will report its first quarter 2021 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, May 13, 2021. The Company will hold a conference call and webcast at 5:00 PM ET the same day. The conference call may be accessed